Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
215 studies found for:    "Scleroderma, Systemic"
Show Display Options
Rank Status Study
21 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
22 Recruiting Zibotentan Better Renal Scleroderma Outcome Study
Conditions: Scleroderma;   Scleroderma Renal Crisis;   Chronic Kidney Disease
Intervention: Drug: Zibotentan
23 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide
24 Unknown  Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan with an anti-fibrotic agent to assess benefit on skin.
25 Completed Effectiveness and Safety of Lidocaine for Scleroderma
Condition: Scleroderma
Interventions: Drug: Lidocaine 2% without vessel constrictor;   Other: Placebo - physiological solution 0,9%
26 Recruiting Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Condition: Scleroderma Lung
Intervention:
27 Active, not recruiting A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Conditions: Pulmonary Arterial Hypertension;   Systemic Sclerosis;   Scleroderma Spectrum of Diseases;   Connective Tissue Disease;   Pulmonary Hypertension
Interventions: Drug: Tadalafil monotherapy;   Drug: Ambrisentan monotherapy;   Drug: tadalafil and ambrisentan
28 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
29 Recruiting Rituximab in Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Rituximab;   Drug: Placebo (NaCl)
30 Completed Premature Coronary Atherosclerosis in Scleroderma
Condition: Scleroderma
Intervention:
31 Completed Finger Hardness Measure in Scleroderma
Condition: Scleroderma
Intervention:
32 Unknown  SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
Conditions: Scleroderma, Systemic;   Sclerosis
Intervention: Behavioral: Telephone Call
33 Not yet recruiting Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Conditions: Scleroderma;   Raynaud's Syndrome
Interventions: Drug: Onabotulinumtoxin A;   Drug: sterile saline solution
34 Completed Oral Type I Collagen for Relieving Scleroderma
Conditions: Scleroderma;   Connective Tissue Diseases
Interventions: Drug: Oral bovine type I collagen;   Drug: Placebo
35 Unknown  AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Hyperimmune caprine serum;   Drug: Albumin
36 Completed Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Condition: Scleroderma
Intervention: Other: Followup survey
37 Terminated
Has Results
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Conditions: Systemic Scleroderma;   Pulmonary Hypertension
Interventions: Drug: Bosentan;   Drug: Placebo
38 Recruiting Calcinosis in a Single-Center Scleroderma Population
Conditions: Scleroderma;   Calcinosis
Intervention:
39 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
40 Completed Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient
Conditions: Scleroderma;   Pulmonary Hypertension
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years